ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "adalimumab and economics"

  • Abstract Number: 1047 • 2017 ACR/ARHP Annual Meeting

    Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing

    Zara Izadi1, Gabriela Schmajuk2, Milena Gianfrancesco3, Laura Trupin4, Kashif Jafri5, Jinoos Yazdany4 and Dhruv Kazi6, 1Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 2San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, San Francisco, CA, 6Department of Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, CA

    Background/Purpose: Adalimumab (ADA) induces and maintains clinical remission in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD) but is an expensive drug. Drug-level and…
  • Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting

    Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany

    Malte Wolff1, Zheng-Yi Zhou2, James Signorovitch2, James W. Shaw3 and Arijit Ganguli3, 1AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 2Analysis Group, Inc., Boston, MA, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.